Dyne Therapeutics (DYN) Share-based Compensation (2019 - 2026)

Dyne Therapeutics (DYN) has reported Share-based Compensation for 8 consecutive years, with $15.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Share-based Compensation rose 42.32% year-over-year to $15.0 million; the TTM figure through Jun 2026 stood at $49.8 million (up 16.46% YoY), while the FY2025 annual figure was $64.9 million, down 10.73% from the prior year.
• Share-based Compensation rose to $15.0 million in Q2 2026 per DYN's latest filing, from $13.1 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $66.0 million in Q3 2025 and bottomed at $3.0 million in Q2 2022.
• Historically, Share-based Compensation has averaged $11.7 million across 5 years, with a median of $7.7 million in 2024.
• Annual changes were most pronounced in 2022 — Share-based Compensation slumped 36.27% — and 2025, when it jumped 654.72%.
• Dyne Therapeutics' Share-based Compensation stood at $3.8 million in 2022, then jumped by 49.53% to $5.7 million in 2023, then jumped by 82.84% to $10.5 million in 2024, then advanced by 7.15% to $11.2 million in 2025, then surged by 33.4% to $15.0 million in 2026.
• Business Quant data shows DYN's Share-based Compensation at $15.0 million in Q2 2026, $13.1 million in Q1 2026, and $11.2 million in Q4 2025.